Publications in collaboration with researchers from Universitat de València (22)

2025

  1. Artificial intelligence: a promising tool for the clinical cardiologist

    Expert Review of Cardiovascular Therapy

  2. NT-proBNP to guide risk stratification after cardiac rehabilitation in patients with ST-segment elevation myocardial infarction

    European Journal of Internal Medicine, Vol. 137, pp. 83-89

2024

  1. Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes—Results from a Multi-Center International Prospective Registry (HOPE-2)

    Journal of Clinical Medicine, Vol. 13, Núm. 9

  2. Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease

    Archivos de Bronconeumologia, Vol. 60, Núm. 4, pp. 226-237

2023

  1. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

2022

  1. The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1466-1478

2021

  1. Association of Left Ventricular Systolic Dysfunction among Carriers of Truncating Variants in Filamin C with Frequent Ventricular Arrhythmia and End-stage Heart Failure

    JAMA Cardiology, Vol. 6, Núm. 8, pp. 891-901

  2. Corrigendum: Facts and Gaps in Exercise Influence on Arrhythmogenic Cardiomyopathy: New Insights From a Meta-Analysis Approach (Frontiers in Cardiovascular Medicine, (2021), 8, (702560), 10.3389/fcvm.2021.702560)

    Frontiers in Cardiovascular Medicine

  3. Facts and Gaps in Exercise Influence on Arrhythmogenic Cardiomyopathy: New Insights From a Meta-Analysis Approach

    Frontiers in Cardiovascular Medicine, Vol. 8

2020

  1. Filamin C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic cardiomyopathy phenotype

    International Journal of Cardiology, Vol. 307, pp. 101-108

  2. Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis

    Frontiers in Endocrinology, Vol. 11

  3. RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy

    International Journal of Cardiology, Vol. 302, pp. 124-130

2019

  1. Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome

    European Journal of Internal Medicine, Vol. 62, pp. 48-53

2018

  1. An Easy Assessment of Frailty at Baseline Independently Predicts Prognosis in Very Elderly Patients With Acute Coronary Syndromes

    Journal of the American Medical Directors Association, Vol. 19, Núm. 4, pp. 296-303

  2. Global Geriatric Assessment and In-Hospital Bleeding Risk in Elderly Patients with Acute Coronary Syndromes: Insights from the LONGEVO-SCA Registry

    Thrombosis and Haemostasis, Vol. 118, Núm. 3, pp. 581-590

2017

  1. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure

    European heart journal. Acute cardiovascular care, Vol. 6, Núm. 8, pp. 685-696

  2. Research update for articles published in EJCI in 2015

    European Journal of Clinical Investigation, Vol. 47, Núm. 10, pp. 775-788

2016

  1. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation

    Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 21, Núm. 2, pp. 150-156

2015

  1. Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure. A Pilot Study.

    JACC: Heart Failure, Vol. 3, Núm. 8, pp. 641-644

  2. Quality of Anticoagulation with Vitamin K Antagonists

    Clinical Cardiology, Vol. 38, Núm. 6, pp. 357-364